Themis Medicare Limited has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a standalone revenue from operations of Rs. 7,653.05 lakhs for the quarter ended March 31, 2026, compared to Rs. 9,013.32 lakhs in the preceding quarter and Rs. 7,170.16 lakhs in the corresponding quarter of the previous year. The standalone net profit for the quarter stood at Rs. 196.56 lakhs, against a profit of Rs. 457.81 lakhs in the preceding quarter and a net loss of Rs. 774.48 lakhs in the corresponding quarter last year.

Themis Medicare Limited is a pharmaceutical company that operates in a single business segment. The board has recommended a final dividend of Re. 0.50 per equity share (50% of face value Re. 1/-) for the financial year ended March 31, 2026, subject to shareholder approval. Additionally, the company has appointed M/s. R. Nanabhoy & Co. as the cost auditor for the financial year 2026-27. The company disclosed that it has received approval for the dissolution of its wholly-owned subsidiary, M/s. Carpo Medicals Limited (UK), and is currently in the process of obtaining final approvals from the Reserve Bank of India.